SYSTEMIC SCLEROSIS: EPIDEMIOLOGY, CLASSIFICATION, PATHOGENESIS, ORGAN INVOLVEMENT, AND TREATMENT - A REVIEW OF PUBLISHED DATA

Authors

  • Yaxyoxanova Moʻtabar Musoxon qizi Impuls tibbiyot instituti Davolash ishi 4 kurs talabasi Author

Keywords:

systemic sclerosis, scleroderma, autoantibodies, interstitial lung disease, pulmonary arterial hypertension, fibrosis, nintedanib, autologous stem-cell transplantation.

Abstract

 Systemic sclerosis (SSc, scleroderma) is a rare, chronic autoimmune connective-tissue disease characterized by the triad of microvascular injury, immune dysregulation with disease-specific autoantibodies, and progressive fibrosis of the skin and internal organs. This article reviews the current understanding of SSc on the basis of published epidemiological and clinical studies, with emphasis on real statistical data - prevalence, incidence, antibody frequencies, organ-involvement rates, survival, and treatment-trial outcomes. According to global meta-analyses, the prevalence of SSc is approximately 18-23 per 100,000 with a marked female predominance of about 4-8:1. The disease is divided into limited and diffuse cutaneous subsets, each associated with characteristic autoantibodies and patterns of organ involvement. Interstitial lung disease and pulmonary arterial hypertension are the leading causes of disease-related death. Recent randomized controlled trials (SENSCIS, focuSSced, SCOT) and the updated EULAR recommendations have substantially expanded the therapeutic options, including antifibrotic and biologic agents and autologous haematopoietic stem-cell transplantation.

References

1. van den Hoogen F, Khanna D, Fransen J, et al. 2013 classification criteria for systemic sclerosis: an ACR/EULAR collaborative initiative. Ann Rheum Dis. 2013;72(11):1747-1755.

2. Denton CP, Khanna D. Systemic sclerosis. Lancet. 2017;390(10103):1685-1699.

3. Bairkdar M, Rossides M, Westerlind H, et al. Incidence and prevalence of systemic sclerosis globally: a comprehensive systematic review and meta-analysis. Rheumatology (Oxford). 2021;60(7):3121-3133.

4. Royle JG, Lanyon PC, Grainge MJ, et al. The incidence, prevalence and survival of systemic sclerosis in the UK Clinical Practice Research Datalink. Clin Rheumatol. 2018;37(8):2103-2111.

5. LeRoy EC, Black C, Fleischmajer R, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol. 1988;15(2):202-205.

6. Steen VD. Autoantibodies in systemic sclerosis. Semin Arthritis Rheum. 2005;35(1):35-42.

7. Tyndall AJ, Bannert B, Vonk M, et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis. 2010;69(10):1809-1815.

8. Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis. 2007;66(7):940-944.

9. Tashkin DP, Roth MD, Clements PJ, et al. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med. 2016;4(9):708-719.

10. Distler O, Highland KB, Gahlemann M, et al. Nintedanib for systemic sclerosis-associated interstitial lung disease (SENSCIS). N Engl J Med. 2019;380(26):2518-2528.

11. Khanna D, Lin CJF, Furst DE, et al. Tocilizumab in systemic sclerosis (focuSSced): a randomised, double-blind, placebo-controlled trial. Lancet Respir Med. 2020;8(10):963-974.

12. Sullivan KM, Goldmuntz EA, Keyes-Elstein L, et al. Myeloablative autologous stem-cell transplantation for severe scleroderma (SCOT). N Engl J Med. 2018;378(1):35-47.

13. Del Galdo F, Lescoat A, Conaghan PG, et al. EULAR recommendations for the treatment of systemic sclerosis: 2023 update. Ann Rheum Dis. 2025;84(1):29-40.

14. Allanore Y, Simms R, Distler O, et al. Systemic sclerosis. Nat Rev Dis Primers. 2015;1:15002.

Downloads

Published

2026-06-11